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CASE AND PEARSO-N (1954) reported that the manufacture of auramine in the
British Chemical Industry between 1910 and 1952 appeared to have attached to
it an occupational hazard ofcausing tumour ofthe urinary bladder. Astatistically
significant excess in the number of deaths from this cause was found and the age
of onset and death from the disease was earlier than in the general population.
These authors pointed out that the essential causal factor in the above risk was
not known and that studies on the use, in contrast to the manufacture, of the
finished products had not been made. It was therefore decided to test auramine
experimentally for carcinogenic activity in the rat (at Manchester) and the mouse
(at Leeds).
Auramine is a yellow dye, used widely to colour cardboard. It has the compo-
sition 4:4'-bis(dimethylamino)benzophenone-imiiie hydrochloride.
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MATERIAL AND METHODS
At Manchester
The rats were males from the
" Wilmslow Wistar
" closed colony and were
8-10 weeks of age at the start of treatment. The standard diet was Scottish Agri-
cultural Industries ret cubes, to which additions were made as required. The
chemical was obtained from the Colours Experimental Department, Huddersfield
Works (I.C.I. Ltd.), being representative of unstandardised batch manufacture
in July, 1955.
Experiment I.-Auramine was dispersed in maize oil and the dispersion, I part
bv weight, added to 39 parts of rat cube powder and 10 parts of malt extract to
give a final concentration in the diet of 0-1 per cent. The ingredients were mixed
with enough water to form a stiff dough, which was extruded through a mincing
machine to form pellets, which were dried in a vacuum oven. Malt extract was
used as a binder, but also improves the palatability of the diet, which was given
ad libitum together with drinking water. Chemical treatment was continued for
87 weeks, when the animals were returned to the basic diet until death.
Experiment 2.-A 2-5 per cent suspension of auramine in arachis oil was
injected subcutaneously in a dose of 0- I ml. per I00 g. body weight on 5 days per
week for 21 weeks.
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At Leeds
The mice were either "stock" albino, bought from a dealer, or belonged to
the CBA strain, which has been inbred in the laboratory since 1933. They were
approximately 12 weeks of age at the start of treatment. The chemical was ob-
tained from the British Drug Houses. The standard diet was rat cake 86, bought
from the N.E. Agricultural Co-operative Society, Aberdeen, and water ad libitum.
Experiments 3 and 4.-Auramine was dissolved in acetone and mixed well with
rat cake powder to give a concentration of 0.1, 0*2 or 0.3 per cent. A stiff dough
was made with water and was dried in the warm oven in flat cakes, which were
fed ad libitum together with drinking water.
RESULTS
Experiment 1.-In Table I it is seen that 92 per cent of the male rats which
received a large dose of auramine over a period of 87 weeks developed hepatomas
TABLE I.-Incidence of Hepatomas in Wilmslow Wistar Rats Receiving Auramine
in the Diet (Experiment 1)
Hepatomas in rats
Number Percentage Weeks of Estimated dying at stated weeks Percentage
of of chemical adminis- total , ------ of
rats Sex in diet tration dose 90-99 100-129 hepatomas
12 .M 0.1 . 9 .360 mg. . 0/5 0/7 0
12 . M . 0.1 . 87 . 10-0 g. 5/6 6/6 . 92
12. M . None - - . 0/6 0/6 0
between the 91st and 122nd week following the start of treatment. The tumours
varied from small single or multiple foci to large masses occupying much of the
liver substance. Accompanying cholangiomatous areas were seen in a third of
the tumour bearing livers. Mild cirrhosis was usually present, associatedwith
minimal bile duct proliferation and hepatic cell nodular regeneration.
A few other tumours were observed. At 99 weeks a rat bearing a small hepa-
toma had in addition a spindle cell malignant tumour at the side of the head.
This was diagnosed as a spindle cell sarcoma, but the possibility of spindle cell
anaplasia in an acoustic duct carcinoma could not be excluded. At 113 weeks,
one rat bearing large multiple hepatomas had a well differentiated adenocarcinoma
of one kidney and also an early transitional cell carcinoma ofthe bladder. Twelve
control rats receiving a diet of rat cake and malt were tumour free at death
between 90 and 129 weeks (Table 1).
Experiment 2.-Twenty of 24 male rats survived 21 weeks of subcutaneous
injection of auramine. The total dose given was 110-120 mg. (Table II). Eleven
rats died between 40 and 89 weeks, 9 with subcutaneous fibrosarcomas andwithout
TABLE II.-Incidence of Tumours in Wilmslow Wistar Rats Receiving Auramine by
Subcutaneous Injection
Tumours in rats
Number Weeks of Estimated dying at stated weeks Percentage
of rats adminis- total r --- of
at start Sex tration dose 40-89 100-113 tumours
24 . M . 21 110-120 mg. -Fibrosarcomas 9/11 2/9 55
-Hepatomas . 1/11 2/9 . 15
8889 INDUCTION OF HEPATOMAS BY AURAMINE
hepatomas, and one with a hepatoma but not bearing a fibrosarcoma. After 100
weeks 2 rats bore fibrosarcomas and 2 hepatomas. In thisexperiment three intes-
tinal carcinomas wereobserved, two inthe caecum at 61 and I13 weeksrespectively,
and one in the duodenum at 113 weeks. One of the former metastasised widely.
Experiments 3 and 4.-The maximum dose which mice would tolerate was
0-2 per cent in the diet. Hepatomas were induced in mice, but in lower incidence
than in rats (Table III). In stock mice, where no hepatomas were present in the
controls living to approximately the same age, hepatomas occurred in both males
and females in the period 50-89 weeks. The difference between the sexes in these
small numbers is not significant. The tumours were noticed with the naked eye
but only attained a large size in one male mouse. No cholangiomas were seen
and the degree of cirrhosis was minimal. In many of the livers there were leuk-
aemic infiltrations.
In CBA mice, although a few hepatomas occurred spontaneously after 80
weeks, an incidence of over 50 per cent was obtained in treated mice ofboth sexes,
the tumours appearing from 60 weeks onwards. The presence of these tumours
was associatedwithmild bile ductproliferation and mild cellular or fibrous cirrhosis
and occasionally with the formation of cholangiomatous areas, i.e. focal non-
neoplastic collections of dilated bile ducts. In untreated CBA mice there was no
cirrhosis. No cholangiomatous areas were seen and only in one male mouse at
114 weeks of age did mild bile duct proliferation occur.
A few other tumours occurred in stock mice but none in CBA mice In a male
treated for 67 weeks there was a reticulum cell sarcoma, especially prominent in
the liver and around the salivary glands, and a deeply invading adenocarcinoma
of the mid-colon. In another male treated for 56 weeks there was a spindle cell
sarcoma ofthe subcutaneous tissues of the flank. This was unlike the reticulum
cell sarcoma in structure, was localised and not associated with parasitic or
other visible infection. In another male treated for 79 weeks there was abenign
interstitial cell tumour of the testis.
Morphology of the tumourS
In all groups the hepatomas ranged in size from microscopical to large masses
occupying the whole liver lobe. In structure theyranged from well differentiated
benign tumours to anaplastic malignant-looking ones. No metastases were seen.
DISCUSSION
Case and Pearson (1954) showed that workers engaged in the manufacture of
auramine ran a risk ofdeveloping papilloma and carcinoma of the bladder. The
present experiments demonstrate that this compound is carcinogenic to the liver
of rats and mice when administered orally in large doses. When administered
subcutaneously to rats in a small dose a few hepatomas occurred together with
subcutaneous fibrosarcomas. The latter are not regarded as necessarily due to
the chemical. Only one bladder tumour was found in an experimental animal
a rat-but this species divergence in location of tumours between man and
rodents is well known in aromatic amine careinogenesis.
In stock mice the hepatomas occurred in livers in which cirrhosis and bile duct
proliferation was minimal. In CBA mice and rats there was mild cirrhosis and bile
duct proliferation with the formation of cholangiomas. These changes were far90 Al. H. C. WILLIAMS AND GEORGIANA '-NT. BONSER
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less advanced than in mice and rats treated with butter yellow (Orr, 1940) or in
mice treated with 3,4:5,6-dibenzcarbazole (Armstrong and Bonser, 1950).
The occasional tumours occurring in other organs ofexcretion, i.e. the kidney,
bladder and intestine wereregarded as chemically induced, but much larger ilum-
bers ofexperimental animals would be needed to establish this with certainty.
SUMMARY
Auramine is carcinogenic to the rat and mouse liver following oral administra-
tion. Hepatomas and fibrosarcomas occurred in the rat following subcutaneous
in ection. These observations lend support to the findings of Case and Pearson
(1954) who reported that the manufacture of auramine was associated with an
occupational hazard of tumour of the urinary bladder.
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